TGFB1 and glioblastoma: Loss of MHC expression, immune suppressive cytokines (TGF-B, IL-10, PGE2), and the expression of PD-L1 in patients with glioblastoma (GBM) contribute to a TME enriched with immunosuppressive factors, rendering these individuals resistant to ICI therapy [31].